Background: The effects of extra-intestinal cancer on the course of inflammatory bowel disease (IBD) are poorly understood. Aim: To evaluate the impact of cancer and its management on IBD outcomes. Methods: A total 80 IBD patients (51 Crohn's disease, 29 ulcerative colitis; 33 men, median age at cancer diagnosis 48 yrs) diagnosed with extra-intestinal cancer were selected from a prospective database. IBD activity and therapeutic requirements (assessed year-by-year) were compared before and after cancer diagnosis, with a control group of patients without cancer matched for gender, birth date, date of IBD diagnosis and IBD phenotype. Results: Paired comparisons of the consecutive periods before and after cancer diagnosis did not show significant changes in median (IQR) percentages of years with active disease (27% vs. 19% [0-53]), while the proportion of patient-years on any immunosuppressant remained stable (26% vs. 28%). Chemotherapy had no significant effect on IBD activity. Compared to controls, patients with cancer had a similar IBD activity and use of anti-TNF, but less use of immunomodulators (19% vs. 25%, p b 0,001) and an increased rate of surgery (4% vs. 2.5%, p b 0,05). Individual variations in IBD activity after cancer diagnosis were not significantly different in patients with cancer and their matched controls. Conclusion: Occurrence of extra-intestinal cancer impacts IBD therapeutic management, with a trend towards less use of immunomodulators and more surgery. In the long-term, cancer diagnoses and treatments do not modify IBD outcomes.
Introduction
Incidences of both inflammatory bowel disease (IBD) 1 and cancer 2 are increasing worldwide, and patients with IBD have an increased lifelong risk of intestinal and extra-intestinal malignancies. 3 Associated IBD has a negative impact on the prognosis of extra-intestinal cancer independent of TNM staging. 4 In a Danish population study, breast cancer patients with CD had a shorter survival compared to breast cancer patients without CD. 5 Conversely, little is known about the evolution of IBD in patients diagnosed with malignancies. On one hand, oncologists usually recommend avoiding immunosuppression, taking into account the risk of relapse or the worsening of the cancer while on immunosuppressive drugs, 6 ,7 yet at the present time approximately 50% of IBD patients are receiving immunomodulators or anti-TNF. In addition, cancer treatment may be associated with IBD reactivation. 8 Moreover, extensive and metastatic cancers may worsen the course of IBD through activation of the inflammatory process. 9 Thus, diagnosis and treatment of extra-intestinal cancer may have significant impacts both on the therapeutic strategies and IBD activity. The aim of the present study was to assess the long-term impacts of diagnoses of extra-intestinal cancer and cancer treatments on IBD outcomes.
Materials and methods

Study population
Patients were enrolled from the MICISTA Registry, a clinical database of all patients with IBD evaluated by the same staff of physicians at St Antoine Hospital from 1975 to the present. This database included 7158 patients as of December 2011. Data were collected retrospectively before 1995 and prospectively afterwards. A history of cancer or current cancer was specifically noted in the database. 10 Patients with diagnoses of extra-intestinal cancer between 1990 and 2009 were selected. Exclusion criteria were a history of intestinal cancer, a follow-up duration below 6 months after cancer diagnosis, skin cancer in patients older than 90-years old, loss to follow up before 1995, and cancer in remission for more than 10 years at the date of IBD diagnosis.
Selected cancer patients were anonymously matched in a 1/3 ratio to 240 patients without cancer (1/3) that constituted a control group. Matching criteria were as follows: gender, birth date (in windows of 5 years), calendar year of diagnosis (windows of 5 years), and disease phenotype (ulcerative colitis [UC] or Crohn's disease [CD]).
Evaluation of disease evolution
IBD activity was assessed year-by-year by analysing the occurrence of flare-ups, hospitalisation, or abdominal surgery. This was codified prospectively at each visit or hospitalisation for every calendar year according to a pre-established gradation from 0 to 5. 10 Each patient-year was considered as active (activity score N 1) if a flare-up requiring a therapeutic modification or a complication occurred during the year, or in the case of chronic active disease, and inactive in the other cases (activity score b 2). Flares and hospitalisations were taken into account only when symptoms were related to active IBD and not therapy-related or cancer-related. Similarly, only intestinal surgical procedures performed for IBD or IBD-related complications were taken into account and codified in the hospitalisation group. Restorative procedures performed in a patient with inactive disease were not included in the grading. Disease evolution was assessed using the same criteria in matched controls, considering a caesura date corresponding to the date of cancer diagnosis of the index case.
Treatment
The principles for the treatment of CD and UC in our unit have been detailed elsewhere. 10 Briefly, disease flares were treated with mesalamine, steroids, or (after 1999) anti-TNF. Maintenance therapy used aminosalicylates, immunomodulators (azathioprine [AZA] as first line drugs, methotrexate in patients unresponsive or intolerant to AZA, or anti-TNF, according to clinical severity. The overall strategy remained mostly unchanged over time; however, there was a distinct tendency to initiate immunosuppressants earlier in the disease course after 1990.
11 Surgery was performed for stenotic complications, extra-parietal complications, neoplasia or intractable forms of CD or UC after well-conducted medical management. In patients with cancer, maintenance and type of immunosuppressants were discussed with the oncologist or the related specialty consultant.
The maximum treatment received by one patient during each calendar year was codified prospectively at each visit or hospitalisation, according to a pre-established gradation (0-5). 10 All treatment(s) were taken into account, even for treatments of short duration.
Statistical analyses
Continuous data are expressed as medians with interquartile range (IQR), and differences between the groups were tested for significance with Wilcoxon rank sum tests for paired or unpaired comparisons as appropriate. Discrete data are given as percentages, and comparisons were made with Pearson chi-squared tests. Periods before and after the diagnosis of cancer were compared both at the individual level and after pooling patient-years within the period considered. The year of diagnosis of cancer was included in the period prior to cancer when the diagnosis of cancer was made before June 30 of the calendar year, and in the subsequent period in the other cases. Inter-individual comparisons considered the period preceding cancer diagnosis and the period subsequent to cancer diagnosis. Only patients having durations of follow-up lasting more than one year both before and after diagnosis of cancer were included in this comparison. Percentages of patient-years were calculated by pooling all patient-years within each consecutive period. Subset analyses were performed in patients who received cytotoxic chemotherapy.
Comparisons with the control group first considered the total of patient-years of the period subsequent to the date of cancer diagnosis in the two groups. In addition, a paired comparison was performed considering the variations of mean individual percentages of years with active disease, the use of immunosuppressants including biologics, and intestinal surgery, respectively, before and after the date of cancer diagnosis, in matched patients of both groups having durations of follow-up lasting more than one year both before and after diagnosis of cancer. Calculations were performed using GBSTAT v10 (Silver Spring, MD, USA). P values b 0.05 were considered significant.
Results
Patients' characteristics
Medical charts of 115 IBD patients with current or recent (diagnosed after 1990) cancer were reviewed. Thirty-five patients were excluded as follows: 18 had a follow-up duration below six months after cancer diagnosis, two patients with a non-melanoma skin cancer were more than 90 years old, 11 patients had their last visit before 1995, and four patients had a cancer in remission for more than 10 years at the date of diagnosis of IBD. A total of 80 patients (33 males and 47 females) with a diagnosis of cancer, were included. Fifty-one had CD and 29 had UC. CD disease location according to the Montreal classification was ileal (L1) in 16 patients, colonic (L2) in 15 
Outcomes
Eight patients eventually died. Causes of death were cancerrelated in 6 patients, cardiovascular disease in one patient and septic shock in one patient following surgery for severe acute colitis. Twenty-two patients were lost to follow-up while free of cancer, and 8 were lost to follow-up while not cancer-free. Among the 42 patients still alive at last evaluation in 2010, 29 were free of cancer and 13 had cancer in treatment.
Individual therapeutic changes after cancer diagnoses
The diagnosis of cancer led to IBD treatment modifications in a large proportion of patients. In the 15 patients who developed cancer before IBD (7 CD, 8 UC), only four (2 CD, 2 UC) received immunosuppressants (AZA, n = 2; methotrexate, n = 2) within the first three years of the disease. In patients who were diagnosed with cancer while having IBD, there was also some restraint shown in starting or continuing immunosuppressants during the three following years: only one patient out of 41 who was not on immunosuppressants at cancer diagnosis was subsequently placed on immunomodulators (methotrexate). Among the 21 patients on AZA, AZA was stopped and not replaced in five patients (2 CD, 3 UC), switched to methotrexate in three patients (2 CD, 1 UC), switched to anti-TNF monotherapy in three patients (3 CD, including one patient with multiple basal cell carcinomas), and maintained in ten patients (7 CD, 3 UC). One of these latter patients had a metastatic breast cancer while others had had curative surgery (four cases of non melanoma skin cancer, one of renal carcinoma, one of thyroid cancer) or were controlled by treatment (two cases of hematopoietic malignancy, one of prostate cancer). Anti-TNF was stopped in two out of the three patients under this regimen at cancer diagnosis. Five patients were operated on during the three years following diagnosis of cancer, in three cases after failure of immunosuppressants: two had intestinal resection for CD and three had a colectomy for UC. In total, when comparing treatment during the three years before vs. the three years after diagnosis of cancer, the use of immunosuppressants decreased from 33 to 25% of patient-years in CD (NS), and from 27 to 16% in UC (NS), without significant difference between CD and UC.
Inter-individual comparisons of IBD activity before and after cancer diagnosis
Fifty-five patients (38 CD, 17 UC) from the cancer group had an IBD follow-up of more than one year both before and after cancer diagnosis. The median value for percentages of years with active disease in individuals was 27% (IQR 0-50) before diagnosis of cancer and 19% (IQR 0-53) afterwards. This difference was not significant (NS). In this subset of patients, the number of patients placed or maintained on immunomodulators or anti-TNF did not change significantly, although nine patients (16%) were switched to or placed on methotrexate afterwards (Table 2) . Likewise, percentages of years on immunosuppressants (including biologics) and with abdominal surgery, respectively, were not significantly different between the two consecutive periods. Pooling allpatient-years confirmed the absence of significant differences between the two periods regarding disease activity (from 32% of patient-years to 28%) and the use of immunosuppressants, including anti-TNF (from 26% of patient-years to 28%). The use of immunomodulators evolved from 25% of a One patient had both laryngeal and oesophagus carcinoma. Impact of the diagnosis and treatment of cancer on the course of inflammatory bowel disease patient-years to 22% (NS). As expected, while considering only calendar years after 1999 (when anti-TNF became available in France), there was an increase in anti-TNF use (from 4 to 11% of patient-years). Finally, the surgical rate tended to increase, from 2.6 to 4.5% of patient-years, but this variation was not significant.
Effects of cytotoxic chemotherapy
Twenty-nine patients (21 CD, 8 UC) with cancer received chemotherapy. In the short term, chemotherapy was not associated with increased IBD activity. Eleven patients (38%) developed a flare during the year of chemotherapy, while disease was active in 49% of cancer patients who did not receive chemotherapy during the year following diagnosis of cancer. When analysing disease activity over the subsequent two years (22 patients treated with chemotherapy had a follow-up of more than 3 years afterwards), the effects of chemotherapy were again not significant: there were 15 patient-years with active disease (33%) in those having received chemotherapy, vs. 25 patient-years with active disease (32%) in the group without chemotherapy.
Comparisons between cancer and control groups
Characteristics of IBD patients constituting cancer and control groups, respectively, are given in Table 3 . There were 629 patient-years of follow-up after cancer diagnosis in the cancer group and 2121 patient-years after the date of diagnosis of the index case in controls. A total of 192 patient-years of active disease (31%) and 52 patient-years with hospitalisation (8%) were observed in the cancer group, compared to 644 patient-years of active disease (30%) and 135 patient-years with hospitalisation (6%), respectively, in controls. These differences were not significant. The proportion of patient-years on steroids without immunomodulators or anti-TNF was not significantly different between the two groups (10% in patients with cancer vs. 9% in controls). The use of anti-TNF was also not different between the two groups: 6% of patient-years in the cancer group vs. 4% in controls. However, immunomodulators were used less frequently in the cancer group (118 patient-years, 19%) compared to controls (517 patient-years, 25%; p b 0.001). Conversely, the number of patient-years with intestinal surgery was increased in the cancer group (4% of patient-years) compared with controls (2.5% of patient-years; p b 0.05). This trend towards decreasing use of immunomodulators and increasing use of surgery in patients with cancer vs. controls was observed in both CD and UC.
To compare the variations in disease activity and therapeutic requirements before and after the date of cancer diagnosis (or index date), 50 patients with cancer and 150 matched controls, respectively, could be analysed. No significant differences were observed between the two groups ( Fig. 1) . 
Discussion
The present study, using a clinical prospective database with prolonged follow-up, showed that extra-intestinal cancer diagnosis was not associated with significant modifications of IBD activity, either when comparing in individuals the periods prior to and subsequent to the diagnosis of cancer or when comparing IBD evolution with IBD patients without cancer. However, diagnoses of extra-intestinal cancer led to some changes in therapeutic strategy, with a lesser use of thiopurines and an increased use of intestinal surgery. This study has several limitations. First, the study design was retrospective, although data were collected prospectively after 1995 from the MICISTA registry. When evaluating disease activity over one year it may be difficult to classify whether intestinal symptoms are related to IBD or to cancer and its treatment if not using a predesigned scale. To avoid this difficulty, we excluded patients with intestinal cancer and a year was considered active only in the case of a flare leading to a change in the treatment of IBD. Second, the study was mono-centric, included a relatively small number of patients, and there was a high rate of loss to follow-up. Third, comparisons of changes in activity and treatment after vs. before diagnosis of cancer are difficult to interpret if one considers that IBD activity tends to decrease with time, that immunosuppressants are used more and more, and that anti-TNF became available in France only in 1999. To overcome these concerns, we evaluated evolutionary and therapeutic changes in comparison with a control group with IBD diagnoses in the same period as the cancer group. Finally, our study did not include a comparative group of cancer patients without IBD for assessing the evolution of cancer. The effect of IBD and its treatment on cancer evolution was beyond the scope of our study.
The diagnosis of cancer had a marked impact on the management of IBD in our cohort. Thiopurines were often stopped or switched to methotrexate, while anti-TNF were used occasionally and avoided in cases of severe malignancy. Our study was not designed to assess the effects of different IBD therapies on the evolution of cancer, and no conclusions can be drawn regarding the validity of these therapeutic options. The impact of immunomodulators on the occurrence of cancer has been assessed in IBD as in other disease states such as rheumatoid arthritis or transplantation. 12, 13 Imputability of thiopurines in the development of non-melanoma skin cancers and lymphomas is well established. 14, 15 The effect of these drugs once the cancer has developed is less known. In colorectal cancer, immunosuppressants (azathioprine, ciclosporine, methotrexate, anti-TNF) have a negative effect on overall survival and disease-free survival. 16 In patients with ocular inflammation receiving immunosuppressants, thiopurines were associated with increased cancer-related mortality. 17 It is not clear that methotrexate conveys similar disadvantages. Indeed, in rheumatoid arthritis, low-dose methotrexate is not associated with an increased cancer risk 18 and high doses of methotrexate are currently used throughout treatment of several cancers including breast cancer, cancer of the urinary tract or squamous cell carcinoma. 19, 20 Finally, the effects of anti-TNF on cancer risk and cancer evolution are debated. In IBD, anti-TNF is associated with an increased risk of melanoma. 21 A recent metanalysis in rheumatoid arthritis concluded that the increased risk of malignancy with anti-TNF was limited to skin cancers. 22 In the case of previous malignancies, the risk of recurrence was not increased by maintenance of anti-TNF treatment. Moreover, several studies examined the effect of anti-TNF for improving cachexia and increasing chemotherapy tolerance in patients with cancers such as non-small cell lung cancer, renal cell carcinoma, and advanced cancer or pancreatic cancer. [23] [24] [25] [26] [27] Some of these phase II studies have reported a positive effect, 23, 26 although these effects have not been confirmed in phase III. 24, 27 In patients with rheumatoid arthritis treated with anti-TNF, the occurrence of cancer during treatment was not associated with a worse prognosis. 28 Finally, anti-TNF may have a protective effect by reducing aggressive metastatic breast cancers at a cellular level. 29 Thus, more studies are needed to better assess the effects of anti-TNF on the evolution of cancer in patients with chronic inflammatory diseases.
The evolution of IBD in patients with concomitant cancer has received little attention in the literature. Axelrad et al. showed that cancer treatment might reactivate IBD in patients in remission. However, the effect of cancer treatment was moderate and dependent upon the type of treatment. 8 Indeed, only ten percent of patients who received cytotoxic chemotherapy developed a flare at 5 years, compared with 36% of those who received hormone therapy or the combination of cytotoxic chemotherapy and adjuvant hormone therapy. In that series there was no important modification of the treatment of IBD concomitant to the diagnosis of cancer: anti-TNF was maintained in the three patients on this regimen and the proportion of patients on immunomodulators decreased slightly, from 22 to 14%. 8 Our study did not examine the effects of hormonotherapy. Cytotoxic chemotherapy was not followed by a significant worsening of disease activity. Modifications of IBD treatment, particularly the decreasing use of thiopurines, were more marked than in the study of Axelrad et al. Despite those modifications, cancer diagnosis did not influence IBD activity, as patients with cancer experience a long-term course of IBD similar to that of IBD patients without cancer.
In conclusion, this study suggests that IBD patients with associated extra-intestinal cancer experience a long-term course of IBD no different from IBD patients without cancer. Gastroenterologists who consider IBD therapeutic options in patients diagnosed with cancer should take into account these results. However, the specific effects of thiopurines, methotrexate, and anti-TNF on the evolution of various extra-intestinal cancers should be studied further to better define the therapeutic strategy for each individual, according to type and site of cancer and prior evolution of IBD.
